A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
Eddy Anglade1, Launa J Aspeslet2, Sidney L Weiss11Lux Biosciences Inc., Jersey City, NJ, USA; 2Isotechnika Inc., Edmonton, AB, CanadaAbstract: Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently a...
Guardado en:
Autores principales: | Eddy Anglade, Launa J Aspeslet, Sidney L Weiss |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/801e6176649a4aa99f9d6d2511d1be30 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis
por: Roesel M, et al.
Publicado: (2011) -
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
por: Hunter RS, et al.
Publicado: (2011) -
Noninfectious uveitis: strategies to optimize treatment compliance and adherence
por: Dolz-Marco R, et al.
Publicado: (2015) -
Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
por: Jane S Myung, et al.
Publicado: (2010) -
A review and update on orphan drugs for the treatment of noninfectious uveitis
por: You C, et al.
Publicado: (2017)